Meeting
2021 ASCO Annual Meeting
Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
Authors
Margaret von Mehren
Fox Chase Cancer Center, Philadelphia, PA
Margaret von Mehren , Sujana Movva , Elizabeth A. Handorf , Priscilla Merriam , Jeffrey A. Morgan , Edwin Choy , Eric Daniel Tetzlaff , Emma Barker , Allisa Cherae Harley , April King , Sahar Matloob , Erika Jerome , Lori Rink , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
NCT03114527
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11515)
DOI
10.1200/JCO.2021.39.15_suppl.11515
Abstract #
11515
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).
First Author: Sujana Movva
Poster
2018 Genitourinary Cancers Symposium
c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression.
First Author: William Kevin Kelly
Poster
2017 ASCO Annual Meeting
Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
First Author: Bernard Tawfik
Poster
2023 ASCO Annual Meeting
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
First Author: Sandra P. D'Angelo